Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | FLT1 | P17948 | 3/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352279 | 0.87 | IRAK4 (0.44) | SYKIRAK4 | |
| SCHEMBL1306299 | 0.83 | AURKB (0.40) | SYKKDRAURKBPRKCIIRAK4 | |
| SCHEMBL1305758 | 0.81 | SYK (0.42) | SYKKDRAURKBIRAK4 | |
| SCHEMBL352309 | 0.81 | SYK (0.42) | SYKKDRAURKBEGFRFLT1 | |
| SCHEMBL1305751 | 0.80 | JAK2 (0.44) | SYKKDRAURKBFLT1FLT3 | |
| SCHEMBL10171507 | 0.77 | IRAK4 (0.52) | SYKKDRAURKBULK1IRAK4 | |
| SCHEMBL12113964 | 0.75 | SYK (0.47) | SYKKDRAURKBULK1CYP11B1 | |
| SCHEMBL352546 | 0.70 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL349701 | 0.69 | IRAK4 (0.42) | SYKKDRAURKBEGFRFLT1 | |
| SCHEMBL349700 | 0.69 | IRAK4 (0.42) | SYKKDRAURKBEGFRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | claimed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | SYK 2/4885KDR 560/4885AURKB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.